VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Sees Significant Drop in Short Interest

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) was the target of a significant drop in short interest in January. As of January 15th, there was short interest totaling 2,441,031 shares, a drop of 27.9% from the December 31st total of 3,385,220 shares. Based on an average trading volume of 1,563,145 shares, the short-interest ratio is presently 1.6 days. Approximately 6.4% of the company’s shares are short sold. Approximately 6.4% of the company’s shares are short sold. Based on an average trading volume of 1,563,145 shares, the short-interest ratio is presently 1.6 days.

Trending Headlines about VistaGen Therapeutics

Here are the key news stories impacting VistaGen Therapeutics this week:

• Neutral Sentiment: Lead-plaintiff deadline and class period: Multiple notices remind investors that the lead-plaintiff deadline is March 16, 2026 and define the alleged class period as April 1, 2024–December 16, 2025; this is procedural but sets the timetable for litigation consolidation and potential claims. ROSEN reminder
• Negative Sentiment: Multiple firms have filed or are soliciting class actions/investigations (Rosen, Pomerantz, Bragar Eagel & Squire, Levi & Korsinsky, Bronstein Gewirtz & Grossman, Faruqi & Faruqi, Schall, DJS, Gross Law and others). That coordinated legal activity suggests elevated litigation exposure; outcomes could include defense costs, settlements or judgment risk that would likely weigh on VTGN’s share price and financing flexibility. Representative filing/notice: Bragar notice

VistaGen Therapeutics Price Performance

VistaGen Therapeutics stock opened at $0.56 on Friday. The business has a 50 day simple moving average of $1.93 and a 200 day simple moving average of $2.95. The company has a market capitalization of $22.04 million, a PE ratio of -0.29 and a beta of 0.31. VistaGen Therapeutics has a one year low of $0.54 and a one year high of $5.14.

VistaGen Therapeutics (NASDAQ:VTGN) last released its quarterly earnings data on Thursday, November 13th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.03). The business had revenue of $0.26 million during the quarter, compared to analysts’ expectations of $0.16 million. Equities analysts anticipate that VistaGen Therapeutics will post -1.77 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently commented on VTGN. Wall Street Zen cut VistaGen Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, December 20th. Jefferies Financial Group reiterated a “hold” rating and issued a $0.90 target price (down from $15.00) on shares of VistaGen Therapeutics in a research note on Wednesday, December 17th. William Blair reiterated a “market perform” rating on shares of VistaGen Therapeutics in a research note on Wednesday, December 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of VistaGen Therapeutics in a report on Wednesday, January 21st. Finally, Maxim Group reaffirmed a “hold” rating on shares of VistaGen Therapeutics in a report on Wednesday, December 17th. Four equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Reduce” and a consensus price target of $0.95.

Hedge Funds Weigh In On VistaGen Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Cubist Systematic Strategies LLC acquired a new stake in shares of VistaGen Therapeutics during the first quarter worth approximately $25,000. Schonfeld Strategic Advisors LLC acquired a new position in shares of VistaGen Therapeutics in the 3rd quarter worth approximately $39,000. Bank of America Corp DE grew its position in VistaGen Therapeutics by 1,068.0% during the 4th quarter. Bank of America Corp DE now owns 21,141 shares of the company’s stock worth $62,000 after acquiring an additional 19,331 shares during the last quarter. Marshall Wace LLP acquired a new stake in VistaGen Therapeutics during the 2nd quarter valued at $69,000. Finally, Millennium Management LLC bought a new position in VistaGen Therapeutics in the 3rd quarter valued at $73,000. 78.39% of the stock is currently owned by institutional investors and hedge funds.

VistaGen Therapeutics Company Profile

VistaGen Therapeutics, Inc (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation medicines for central nervous system disorders. Incorporated in Delaware in 1998 and headquartered in South San Francisco, California, VistaGen applies advanced human pluripotent stem cell technologies to accelerate drug candidate validation and optimization. The company’s core focus is on addressing unmet medical needs in major depressive disorder, neuropathic pain and dermatological conditions.

The company’s lead candidate, AV-101, is an oral prodrug designed to modulate glutamatergic neurotransmission via the N-methyl-D-aspartate (NMDA) receptor pathway, with clinical programs targeting major depressive disorder and neuropathic pain.